KSQ-001: A CRISPR/Cas9-engineered tumor infiltrating lymphocyte (eTILTM) therapy for solid tumors-MedSci.cn

KSQ-001: A CRISPR/Cas9-engineered tumor infiltrating lymphocyte (eTILTM) therapy for solid tumors

Schlabach, M; Colletti, N; Hohmann, A; Wrocklage, C; Gannon, H; Falla, A; Tubo, N; LaMothe, RA; Bullock, C; Mitchell, PT; Hafeez, N; Sathithloetsakun, S; Grasberger, PE; Le Mercier, I; Garrett, TE; Keegan, S; Shenker, S; Franco, C; Stegmeier, F; Kryukov, GV; Cadzow, L; Benson, M